Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA Pulmonary Division Director Jenkins To Head ODE II; Bilstad To Head QA

Executive Summary

FDA Pulmonary Drug Products Division Director John Jenkins, MD, has been selected to head FDA's Office of Drug Evaluation II, beginning April 25.

You may also be interested in...



FDA And EMEA To Compare Regulatory Approaches Used In 1998 NME Cohort

FDA and the European Medicines Evaluation Agency will conduct a joint assessment of the approaches used by the two agencies in the 1998 cohort of new molecular entity reviews.

FDA And EMEA To Compare Regulatory Approaches Used In 1998 NME Cohort

FDA and the European Medicines Evaluation Agency will conduct a joint assessment of the approaches used by the two agencies in the 1998 cohort of new molecular entity reviews.

FDA ODE II Overhaul Continues: Rarick Returns, Sobel Moves Up

FDA is completing a change of the guard in the Office of Drug Evaluation II with the appointment of Reproductive & Urologic Drug Products Division Director Lisa Rarick, MD, as ODE II deputy director.

Related Content

UsernamePublicRestriction

Register

PS034039

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel